Clinical Trial News | Discover the new PCSK9-I

Exom starts an observational prospective multicenter study to assess the long-term effectiveness and tolerability of a new  PCSK9-I inhibitor in the real life clinical practice, in a severe hypercholesterolemic population resistant to full dosage statins. The study...

Exom Group launched Genius ENGAGE™

The first electronic Informed Consent fully combined with the eTMF Exom Group, the Human Digital CRO, has launched Genius ENGAGE™, the industry’s first ever electronic Informed Consent solution whose digital workflow is fully combined with the eTMF,  and integrated...